( October 15, 2026, 12:30 PM EDT) -- NEW ORLEANS — Louisiana submitted a letter to the Fifth Circuit U.S. Court of Appeals after it heard oral argument in a case disputing whether the U.S. Food and Drug Administration’s 2023 decision that removed the in-person dispensing requirement for mifepristone, a drug used in medication abortions, was unlawful; Louisiana argues that a complaint filed by three states and a motion in the U.S. Supreme Court illustrate how a favorable decision in the Fifth Circuit “will eliminate the flood of FDA-approved mifepristone into the State.”...